Project description DEENESFRITPL Novel Crohn’s disease treatment helps to achieve long-term remission Crohn's disease (CD) is a chronic inflammatory bowel disease affecting millions of people worldwide and impacting their quality of life. French company Exeliom Biosciences aims to develop a novel drug for CD patients, named EXL01, based on the unique commensal bacteria Faecalibacterium prausnitzii. In contrast to current CD treatments, EXL01 achieves long-term remission in mild-to-moderate cases without side effects. Exeliom Biosciences has built an operational team of scientific and business advisors. The company has established collaborations with key industrials partners, developed the manufacturing process and tested the drug in preclinical studies. The EU-funded EXL01 project will support the phase 2a clinical trial and scale-up of the manufacturing process. Show the project objective Hide the project objective Objective Crohn's disease is a Chronnic Inflammatory Bowel disease affecting over 1.4 million people worldwide. It is the fourth chronic condition impacting the most severely patients’ quality of life, ahead of cancer, visual impairments, and chronic respiratory conditions. Crohn’s disease is an intestinal disorder causing chronic inflammation of the gastrointestinal tract. It is mainly diagnosed in young people, from 15 to 40 years old. Patients experience excruciating symptoms such as abdominal pain, diarrhea, joints pain and swelling. In some cases, it may even be mortal. Besides this tremendous health impacts, the disease is associated with over €30 billion of annual costs. Exeliom Biosciences is an innovative French AME created in 2016 with a mission to bring a new life to Crohn’s Disease patients. The company is developing a game-changing drug, named EXL01, which relies on a unique commensal bacteria Faecalibacterium prausnitzi. Unlike current Crohn’s Disease treatments, EXL01 achieves long-term remission in mild-to-moderate Crohn’s disease patients without any side effect. It will decrease the number of existing treatments which present a very bad benefit/risk ratio and strong costs in mild-to-moderate patients. Therefore, besides its tremendous health impact, EXL01 will decrease by several million direct and direct costs related to Crohn’s Disease. Exeliom Bioscience has built a team of 5 operational people, and board of 6 scientific and 5 business advisors. The company has also strong collaborations with key international centres and industrials. The company has its own manufacturing process to produce the drug substance and EXL01 has been tested in preclinical studies. Thanks to the EIC Accelerator, Exeliom will reach phase 2a clinical trial and scale-up its manufacturing process. Eventually, EIC Accelerator would place Exeliom on a trajectory to become a global leader in the treatment of Crohn’s Disease. Fields of science engineering and technologymechanical engineeringmanufacturing engineeringnatural sciencesbiological sciencesmicrobiologybacteriologymedical and health sciencesclinical medicinegastroenterologyinflammatory bowel diseasemedical and health sciencesclinical medicineoncology Keywords Crohn’s Disease Inflammatory Bowel Disease Chronic Disease Bacterium commensal bacteria Microbiology Gut Microbiota Anaerobic production process Faecalibacterium prausnitzi Quality of life Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-EIC-SMEInst-2018-2020-3 Funding Scheme SME-2 - SME instrument phase 2 Coordinator EXELIOM BIOSCIENCES Net EU contribution € 2 501 528,75 Address 67 RUE DES GODRANS 21000 Dijon France See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Bourgogne-Franche-Comté Bourgogne Côte-d’Or Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 3 573 612,50
